PTN

Business Context and Reporting Period

Company: Palatin Technologies, Inc. (PTN)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended September 30, 2025

Business Overview: Palatin is a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor (MCR) system for obesity, ocular diseases, and inflammatory conditions. The Company previously commercialized Vyleesi, which was sold to Cosette Pharmaceuticals in December 2023.

Listing Status: Trading was suspended on NYSE American in May 2025 due to low stock price and moved to OTCQB. Trading was reinstated on NYSE American on November 12, 2025, following a public offering.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased from $0 to $8.85 million, driven entirely by a new agreement with Boehringer Ingelheim. This included $2.34 million for patent assignment, $6.49 million for a research milestone, and $17,550 in FTE reimbursements.
• Profitability Shift: The Company reported a net income of $4.68 million compared to a net loss of $7.82 million in the prior year, primarily due to the recognition of collaboration revenue.
• Expense Reduction: Total operating expenses decreased by approximately 46% to $4.19 million. Research and Development (R&D) expenses dropped significantly to $2.53 million from $5.74 million, attributed to reduced spending on MCR programs.
• Stock Structure: A 1-for-50 reverse stock split was effective August 11, 2025. All share and per-share data in the filing have been retroactively adjusted.

Outlook, Risks, and Subsequent Events

• Liquidity and Going Concern: As of September 30, 2025, cash was $1.27 million against $8.22 million in current liabilities. However, management concluded that substantial doubt about the Company's ability to continue as a going concern no longer exists due to subsequent cash inflows: approximately $5.4 million received from Boehringer Ingelheim in October 2025 and approximately $16.9 million in net proceeds from a public offering closed on November 12, 2025.
• Pipeline Updates:
  • Obesity: Co-administration of bremelanotide with tirzepatide reported positive topline data in Q1 2025. IND filings for a novel once-weekly MC4R peptide and oral small molecule (PL7737) are projected for Q1 2026.
  • Ocular: PL9643 (dry eye disease) completed a Phase 3 trial; a second Phase 3 is targeted for H1 2026.
  • Gastrointestinal: PL8177 (ulcerative colitis) reported positive Phase 2 topline data in Q1 2025.
• Risks:
  • Government Shutdown: A U.S. government shutdown in October 2025 caused furloughs at the SEC and FDA, potentially delaying regulatory reviews and capital market access.
  • Litigation: The Company is defending a breach of contract lawsuit filed by H.C. Wainwright & Co. LLC regarding an engagement agreement. No accrual has been recorded as a loss is not considered probable.
  • Financing Dependence: The Company expects to incur losses for the foreseeable future and requires additional funding to complete clinical trials.

Investor Verification Checklist

• Revenue Sustainability: Verify the timing and probability of future milestone payments from Boehringer Ingelheim, as the current revenue spike is non-recurring.
• Cash Runway: Confirm the actual cash balance post-November 2025 offering and assess if it is sufficient to fund operations through the next 12 months without further dilution.
• Listing Compliance: Monitor the stock price to ensure continued compliance with NYSE American listing standards following the reinstatement.
• Legal Exposure: Track the status of the H.C. Wainwright lawsuit for potential financial impact.
• Clinical Milestones: Validate the timelines for upcoming IND filings (Q1 2026) and Phase 3 trials for PL9643.